Amerisafe (AMSF) Q3 Earnings Meet Estimates

Amerisafe reported Q2 2026 net premiums earned of $77.3 million, up 11.4% year over year, while pre-tax underwriting income fell 37.9% to $3.6 million. Net combined ratio widened to 95.4% from 91.7%. For H1 2026, net premiums earned rose 10.2% and net income was $22.7 million. Amerisafe cited higher prior-period write-offs and investment gains.

AMERISAFE INC (AMSF) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 d122285dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Guillermo A. Ramos EVP & CFO AMERISAFE 337.463.9052 AMERISAFE ANNOUNCES 2026 SECOND QUARTER RESULTS Reports 11.4% Growth in Net Premiums Earned DeRidder, LA – July 21, 2026 – AMERISAFE, Inc. ( Nasdaq: AMSF ), a specialty pr

Moderna (MRNA) and Merck reported a 42% reduction in melanoma recurrence or death in a Phase 3 trial of Moderna's cancer vaccine. Shares fell 17.6% after data leaked early. The trial tested intismeran autogene with Merck's Keytruda. Moderna reported Q2 2026 loss of $782m on $145m revenue.

Moderna and Merck's experimental melanoma vaccine, combined with Keytruda, reduced recurrence or death risk by 42% in a Phase 3 trial. Despite positive results, Moderna's shares fell 18%, likely due to high investor expectations. The vaccine is personalized using mRNA technology, targeting unique tumor mutations. Trial data showed 82.2% of patients treated with the vaccine and Keytruda were alive without recurrence after two years, compared to 70% with Keytruda alone.

Vertex Pharmaceuticals reported positive Phase III results for povetacicept, showing a 52% reduction in proteinuria in kidney disease patients. The drug's safety profile was similar to placebo. Vertex also discussed inaxaplin's potential in treating APOL1-mediated kidney disease, with Phase III AMPLITUDE trial results expected early next year. The company is engaging with payers for povetacicept's commercial coverage.

Novartis' remibrutinib showed 31.2% to 35.2% lower annualized relapse rates vs. teriflunomide in two late-stage MS trials. Both trials met primary endpoints. Novartis plans global regulatory filings. Analysts estimate potential peak sales over $4B, though not company guidance.